AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
William Blair Initiates Coverage on CDNA with Market Perform Rating
ByAinvest
Sunday, Aug 31, 2025 4:43 am ET1min read
CareDx (CDNA) has been initiated with a "Market Perform" rating by William Blair analyst Andrew Brackmann. The initiation marks a new coverage by the investment bank, which currently has no price target specified for the stock. CareDx operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. The average target price for CDNA is $22.50, with a high estimate of $28.00 and a low estimate of $14.00, indicating an upside of 76.47% from the current price of $12.75.
William Blair analyst Andrew Brackmann has initiated coverage on CareDx, Inc. (CDNA), assigning the stock a "Market Perform" rating. This marks the investment bank's entry into the company's coverage, with no price target specified for the stock at this time. CareDx operates as a precision medicine company specializing in the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers.CareDx offers a range of diagnostic services, including testing solutions like AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung. These services are designed to support the pre- and post-transplant patient journey, utilizing genomics-based information to improve transplant outcomes.
The average target price for CDNA is $22.50, with estimates ranging from $14.00 to $28.00. This indicates an upside potential of 76.47% from the current price of $12.75. The company's revenue is expected to reach $367 million in 2025 and $407 million in 2026, driven by a growing market and government initiatives like the IOTA model.
William Blair's analysis highlights CareDx's strong position within the transplant ecosystem, which is dominated by 250 cardiothoracic and abdominal transplant centers, and a total addressable market (TAM) of $8 billion. The company's expanding portfolio of offerings, growing transplant cases, and leading share in testing services are expected to contribute to sticky, predictable, and profitable revenue growth.
References:
[1] https://www.williamblair.com/News/CareDx-Inc-Initiation
[2] https://www.marketscreener.com/news/william-blair-initiates-coverage-on-caredx-with-market-perform-rating-ce7c50d9d88df324
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet